Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease.
about
Magnesium for treating sickle cell disease2015 Clinical trials update in sickle cell anemiaMagnesium for treating sickle cell diseaseDeveloping treatment for sickle cell disease.Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.The Role of Nutrition in Sickle Cell Disease.Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options.Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway.Pharmacotherapy in sickle cell disease--state of the art and future prospectsIon transport pathology in the mechanism of sickle cell dehydration.A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype).The genomics of new drugs in sickle cell disease.Growth and nutritional status of children with homozygous sickle cell disease.Malnutrition in Sickle Cell Anemia: Implications for Infection, Growth, and Maturation.Investigational drugs in sickle cell anemia.Determinants of erythrocyte hydration.Novel therapies targeting the endothelium in sickle cell disease.Erythrocyte adhesion is modified by alterations in cellular tonicity and volume.Pathophisiology of sickle cell disease and new drugs for the treatment.Simultaneous determination of low free Mg2+ and pH in human sickle cells using 31P NMR spectroscopy.Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial.
P2860
Q24193246-0C9AEBBC-59D5-42F2-BF05-F7446F8512B5Q28086979-4B19DF0D-463E-4579-BE77-1BD55B5F0100Q29994630-5765E657-A8FC-46D3-990B-C5932E5F525AQ34628666-42D87328-B669-4329-88A1-8661F9308DA5Q34750534-0269EB0B-26C2-4930-8B83-9E2E8096C0E1Q34891505-BC698FD8-D0FB-4735-AD58-979284B9C9F2Q34941213-C26CC662-642A-4484-A77D-D9BC1735E979Q35076604-F1B1A238-B786-406C-83E2-D421CE7341D1Q35191429-0687F3B6-1906-424E-8E74-7B65E26C713FQ35220342-BC36DAF4-45B4-4BCE-BC70-25B9DB814882Q35993299-9FD8868A-2A05-4385-9315-ADC67CE0E2E5Q36115743-116946A6-4D61-40F1-AA01-8E00C4097952Q36540959-E4A1D25B-1ACE-49D9-A313-CCC58A3AF82BQ36596719-50CF4054-FE7A-4680-9308-5FD3C6C72983Q37252542-3CA4C149-DCC4-4849-86AD-8C9C2894BDA5Q37359292-8D9EFD02-491A-4A49-82FC-1FC68419F065Q37603352-3A448478-6A8D-46CB-839D-409976242686Q37698164-C0871F83-CA4F-414D-94B2-6A859025AE05Q37930655-CD8D1087-CF16-45BD-8318-8CA6D9E89BF6Q38319921-E0725E8A-21BE-4EFF-815F-BF1F0C74B7ABQ41777376-2A7FA084-C712-488B-A37E-545A15D485CDQ44151451-C7478CCA-FA92-463B-8405-CB4C19EFA5A8Q46908502-4FAD5E55-C10E-4703-84A7-E919E5E20D60Q50547239-12C90BA0-9856-4CCF-B57E-4B8B13958325
P2860
Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Oral magnesium pidolate: effec ...... ents with sickle cell disease.
@ast
Oral magnesium pidolate: effec ...... ents with sickle cell disease.
@en
type
label
Oral magnesium pidolate: effec ...... ents with sickle cell disease.
@ast
Oral magnesium pidolate: effec ...... ents with sickle cell disease.
@en
prefLabel
Oral magnesium pidolate: effec ...... ents with sickle cell disease.
@ast
Oral magnesium pidolate: effec ...... ents with sickle cell disease.
@en
P2093
P2860
P1476
Oral magnesium pidolate: effec ...... ents with sickle cell disease.
@en
P2093
Brugnara C
De Franceschi L
Galacteros F
Tchernia G
P2860
P304
P356
10.1046/J.1365-2141.2000.01861.X
P407
P577
2000-02-01T00:00:00Z